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Successful treatment of endotension and aneurysm
sac enlargement with endovascular stent graft
reinforcement
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Abdominal aortic aneurysm (AAA) enlarges after successful endovascular repair because of endoleak, which is persistent
blood flow within the aneurysm sac. In the absence of detectable endoleak, AAA may still expand, in part because of
endotension, which is persistent pressurization within the excluded aneurysm. We report three patients who underwent
successful endovascular AAA repair using the Excluder device (W. L. Gore & Associates, Flagstaff, Ariz). Although their
postoperative surveillance showed an initial aneurysm regression, delayed aneurysm enlargement developed in all three,
apparently due to endotension. Endovascular treatment was performed in which endograft reinforcement with a
combination of aortic cuff and iliac endograft extenders were inserted in the previously implanted stent grafts. The
endograft reinforcement procedure successfully resulted in aneurysm sac regression in all three patients. Our study
underscores the significance of increased graft permeability as a mechanism of endotension and delayed aneurysm
enlargement after successful endovascular AAA repair. In addition, our cases illustrate the feasibility and efficacy of an
endovascular treatment strategy when endotension and aneurysm sac enlargement develops after endovascular AAA
repair. ( J Vasc Surg 2007;46:124-7.)An abdominal aortic aneurysm (AAA) may continue to
enlarge despite a technically successful endovascular repair
due to endoleak or endotension.1 Endotension has been
described with the use of the Excluder Endoprosthesis
(W. L. Gore & Associates, Flagstaff, Ariz) leading to con-
version for graft explantation and open repair.2 Treatment
modalities for this entity are at present subject to debate.
We present three case reports of patients who under-
went endovascular AAA repair with the Excluder device in
whom postoperative surveillance demonstrated aneurysm
expansion as a result of endotension. The patients were
successfully treated by reinforcing the Excluder endograft
device. Our study suggests that increased permeability of
the first-generation Excluder endografts favors the devel-
opment of endotension and discusses an effective alterna-
tive to open repair for the treatment of endotension in
high-risk patients.
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From October 2000 to July 2004, three patients underwent
endovascular AAA repair using the first-generation Excluder de-
vice. Detailed clinical information about their treatment course is
presented in the Table. The initial AAA diameter, measured as the
maximum distance between the outer aneurysm walls, was 5.5 cm
in patient 1, 5.9 cm in patient 2, and 5.8 cm in patient 3. All
patients had an uneventful recovery after the operation.
During their follow-up surveillance with contrast computed
tomography (CT) imaging, all three patients showed AAA enlarge-
ment without detectable endoleak. The diameters of their AAAs
had enlarged to 6.3 cm, 6.5 cm, and 6.3 cm, respectively (Table).
There was no evidence of aortic neck dilatation or stent graft
migration. Further investigation with angiography and color du-
plex ultrasonography failed to detect persistent blood flow in the
aneurysm sac. Intrasac pressure of the excluded AAAwas measured
in patients 1 and 2 by a translumbar approach, which confirmed an
equivalent aneurysm sac pressure with the systemic aortic pressure.
Because of their medical comorbidities, the endotension was
treated with an endovascular approach. Through bilateral groin
cutdowns, an Excluder aortic cuff was implanted in the main
portion of the bifurcated device. We then implanted a bilateral
Excluder iliac endograft in the respective iliac limb. In two of our
patients, the new generation and less permeable Excluder stent
grafts were used in the second procedure. This endograft reinforce-
ment essentially doubled the thickness of stent-graft coverage.
Balloon dilation was then performed in all reinforced stent grafts.
Table. Clinical information of patients treated with endovascular reinforcement procedure
Patient
No
Age (y)/
Sex
Medical
comorbidities
AAA
diameter
Initial
EVAR
date Device implanted*
Diameter of
enlarged
AAA in
follow-up CT
scan/date
Date of endograft
reinforcement
procedure
Reinforced device
implanted*
Follow-up
diameter of
AAA
regression/date
1 63/M CAD,
hypertension,
DM
5.5 cm Jan 2001 1. Aortic main device
(26 mm  14.5
mm  14 cm)
2. Contralateral iliac
limb (16 mm 
11.5 cm)
6.3 cm/
Jan 2003
Mar 2003 1. Aortic cuff (26 mm
 3.3 cm) in the
main device
2. Iliac device (16
mm  13.5 cm) in
each iliac limb
5.3 cm/
Sep 2005
2 82/M Stroke,
hypertension,
DM
5.9 cm Jul 2002 1. Aortic main device
(26 mm  14.5
mm  16 cm)
2. Contralateral iliac
limb (16 mm 
11.5 cm)
6.5 cm/
Apr 2005
Jun 2005 1. Aortic cuff (26 mm
 3.3 cm) in the
main device
2. Iliac device (16
mm  13.5 cm) in
each iliac limb
6.0 cm/
Apr 2006
3 76/M Renal failure,
CAD stroke
5.8 cm Nov 2003 1. Aortic main device
(28.5 mm  14.5
mm  14 cm)
2. Contralateral iliac
limb (16 mm 
11.5 cm)
6.3 cm/
Nov 2005
Nov 2005 1. Aortic cuff (26 mm
 3.3 cm) in the
main device
2. Iliac device (16
mm x 13.5 cm) in
each iliac limb
5.6 cm/
Nov 2006
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair; CT, computed tomography; CAD, coronary artery disease; DM, diabetes mellitus.
*Gore Excluder devices (W.L. Gore & Associates, Flagstaff, Ariz).
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July 2007126 Kougias et alA completion angiogram in all patients showed fully patent
endograft segments without appreciable device-related luminal
narrowing. All patients tolerated the procedure well, without
complication. In patient 1, the follow-up CT scan 6 months later
showed no endoleak and a markedly reduced aneurysm sac mea-
suring 5.3 cm  5.1 cm in greatest diameter, which represents
aneurysm sac shrinkage of 10 mm after the endograft reinforce-
ment procedure. The follow-up CT scan 6 months later in patient
2 showed his aneurysm sac had reduced to 6.2 cm at its greatest
diameter without endoleak. A 12-month surveillance CT scan
showed an aneurysm sac of 6.0 cm without endoleak. In patient 3,
his follow-up CT scan at 6 and 12 months showed the aneurysm
sac had reduced to 5.6 cm in diameter without endoleak.
DISCUSSION
Our report is notable because it underscores that in-
creased endograft permeability may result in endotension
and constitutes an important mechanism of late aneurysm
sac enlargement after early successful endovascular repair.
More important, our report highlights a novel endovascu-
lar treatment strategy of endotension-induced aneurysm
sac enlargement.
Delayed aneurysm expansion developed after endovas-
cular repair in all three of our patients. Despite a thorough
investigation with imaging studies, we were unable to
detect an endoleak. In two of these patients, the presence of
a pressurized aneurysm sac was confirmed with intra-aneu-
rysm pressure measurement. The use of sac cannulation for
intra-aneurysm pressure measurement after endovascular
repair has previously been reported by our group.1 Baum et
al3 also described two approaches to intra-aneurysm pres-
sure assessment, which included a direct translumbar access
with puncture of the aneurysm sac or a selective cannula-
tion of the inferior mesenteric artery by either the superior
mesenteric artery or the hypogastric arteries. We used the
former approach to confirm the presence of an endotension
in our first and second patients.
The exact mechanism of persistent sac pressurization
without detectable endoleak remains poorly understood.
Some authors suggest that endotension is a result of direct
pressure transmission from the endograft lumen to the
aneurysm sac.4,5 In addition, low-flow endoleak that is not
detected with imaging modalities, and subsequent enzy-
matic degradation of the accumulated thrombus, might
lead to aortic aneurysmal wall weakening.6
A recently emerging theory claims that endotension
can be the result of pressure transmission and fluid accu-
mulation that is facilitated by increased graft porosity,
which is the case with the thin polytetrafluoroethylene
(PTFE) grafts.7 This notion is supported by findings from
the recent study of Trocciola et al,8 who reported transu-
dation of serum components in an animal model of aortic
aneurysm that had been excluded with an expanded PTFE
stent graft. By comparison, aneurysm exclusion with a
Dacron stent graft resulted in significantly less pressure
transmission in the aneurysm sac and demonstrated greater
thrombus organization. This theory appears to be more
relevant clinically, supported by the observation that thefirst generation Gore Excluder device is associated with less
aneurysm sac shrinkage compared with the other devices
approved by the United States Food and Drug Adminisra-
tion.9,10
Because all three of our patients had received the first
generation Gore Excluder device, we postulated that their
aneurysm sac enlargement might have been a device-spe-
cific phenomenon. There has been a manufacturing alter-
ation in the current Gore Excluder device, with additional
fabric layer reinforcement to decrease the endograft poros-
ity. The clinical significance of this device modification with
regards to a decreased incidence of endotension or sac
enlargement remains to be validated.
The clinical significance of endotension is not fully
elucidated. Despite the documented cases of endotension
in patients with the Excluder stent graft, the incidence of
endotension-related rupture is very low. Kong et al2 re-
viewed data from the multicenter phase I and II clinical
trials of the Excluder endograft and reported no endoten-
sion-related aneurysm rupture.2
More intriguing were the findings of Mennander et
al,11 who treated expectantly five patients with endoten-
sion. The aneurysm sac was ruptured in three of their
patients during the follow-up, without associated hemor-
rhage, confirming a continuous increase in sac size and
aneurysmal wall tension in the presence of a very effective
endograft seal. One of the patients underwent exploratory
laparotomy for presumed aneurysm rupture and abdominal
pain. Intraoperatively, he was found to have a ruptured
aneurysmal sac, no evidence of bleeding, and a large
amount of gelatinous material that had been evacuated
from the sac into the abdomen. It is evident from this study
that sac enlargement is not always associated with blood
flow inside the sac, and that continuous filtration of tran-
sudativematerial through the graft may result in sac rupture
without major clinical sequelae.
The findings of this study support the basis of our
treatment strategy in that endograft reinforcement de-
creased the device porosity and therefore reduced transu-
dative filtration leading to the resultant aneurysm sac
shrinkage. As evidenced by our results, complete relining
and isolation from the circulation of the old endograft with
another bifurcated device is not necessary. Minimizing the
surface of increased porosity that comes into contact with
the blood seems to suffice in restoring the pressure equilib-
rium across the device, therefore abrogating the transuda-
tive process.
The management strategies of observed endotension
are still evolving. There is a general agreement that a
thorough investigation with CT scan, contrast-enhanced
duplex ultrasonography, and angiography should be un-
dertaken to rule out the presence of an endoleak, which is
sometimes difficult to detect but can be treated with min-
imally invasive means.12 Treatment remains controversial.
The report by Mennander et al11 indicates that conservative
treatment with close observation only is justified if the
endoleak is ruled out with well-performed imaging studies.
A recent consensus report, however, advocated that aneu-
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 1 Kougias et al 127rysm sac enlargement associated with endotension needs to
be treated.13
For patients who are medically fit to undergo an open
procedure, conversion to open aneurysmorrhaphy should
be considered. Our cases demonstrate that a complete
endovascular strategy with endograft reinforcement to de-
crease endograft porosity is both feasible and effective in
patients with aneurysm sac enlargement, particularly those
treated with the first generation of the Excluder device.
A few technical issues of the relining procedure are
worth further discussion. The entire old endograft was
“relined” with the aortic cuff and the extension limbs. The
only exception was the area of the main body that remained
uncovered by the aortic cuff. To protect the flow divider,
the aortic cuff was deployed flush with the proximal end of
the main body, offering a 0.7-cm clearance off the flow
divider. We found that positioning the deployment sheath
close to the flow divider facilitates the positioning and
precise deployment of the aortic cuff.
We used iliac limbs slightly longer than those placed upon
the original procedure. We had two reasons for doing this: on
the ipsilateral side,wewanted to gain fixation length and avoid
migration problems in the future; whereas on the contralateral
side, we wanted to make sure that we fully overlapped the old
attachment site all the way up to the flow divider. Although
one could argue that increasing the fixation lengthmight have
sealed an undetectable distal type I endoleak, we believe that
this unlikely given the detailed imaging we used before reop-
eration. Finally, reinforcing a small endograft may be risky
because of endograft redundancy and the potential of lumen
compromise. Until more experienced is accumulated, we
would not recommend this procedure for patients with iliac
vessels sized10 mm.
CONCLUSION
Our findings support the concept of endotension second-
ary to increased permeability as a mechanism of aneurysm
expansion after endovascular repair. Although more studies
are needed to clarify the natural history and pathophysiology
of this process, endovascular repair should be considered as a
valid treatment option in the event of continuous aneurysm
expansion in high-risk patients. Our report underscores theimportance of long-term surveillance after endovascular AAA
repair to ensure treatment success.
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